Drug Update · Infectious Disease

AREXVY Expanded for Adults 18–59 at Increased RSV Risk

August 24, 2026

Updated labeling date

July 27, 2026

Indication

Prevention of RSV LRTD in individuals 60 years and older; individuals 18 through 59 years at increased risk for LRTD caused by RSV [1][6]

Pivotal efficacy - LRTD

82.6% reduction in risk of RSV-associated LRTD (first season analysis) [5]

Pivotal efficacy - severe LRTD

94.1% reduction in risk of severe RSV-associated LRTD (first season analysis) [5]

Dose

Single intramuscular dose 0.5 mL after reconstitution [1][6]

Notable safety signals

Postmarketing signal for Guillain-Barré syndrome within 42 days; common reactions include injection site pain, myalgia, fatigue, headache, arthralgia [1][6][5]

Clinical Perspective

Clinicians who provide adult vaccination and primary care clinicians caring for adults now have an updated FDA‑approved indication to discuss AREXVY for active immunization to prevent RSV-associated lower respiratory tract disease in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV, as well as for individuals 60 years of age and older, per the revised prescribing information ^[1]^[4]^[2]. The source‑confirmed data support use of a single intramuscular dose of AREXVY, 0.5 mL after reconstitution, with safety information that includes common local and systemic reactions and a postmarketing signal for Guillain-Barré syndrome to include in risk discussions ^[1]^[4]^[3]. Key practical questions remain about the duration of protection after a single dose in the 18 through 59 years at‑risk group and the role, timing, and safety of repeat vaccination across RSV seasons?

Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases) · Infectious Diseases

AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) labeling was updated in July 2026 to include active immunization for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV, in addition to the existing indication for individuals 60 years of age and older ^[1]^[4]. The updated prescribing information specifies a single intramuscular dose of AREXVY and includes postmarketing safety information relevant to adult vaccination discussions ^[1]^[4]^[3].

Clinical Context

AREXVY is an adjuvanted recombinant respiratory syncytial virus vaccine marketed by GlaxoSmithKline Biologicals SA and is indicated for active immunization to prevent RSV-associated lower respiratory tract disease (LRTD) in older adults and in adults 18 through 59 years who are at increased risk for LRTD caused by RSV ^[1]^[4]^[2]. The updated label and prescribing information were posted in July 2026 on the FDA and DailyMed sites and summarize pivotal efficacy results from the randomized, placebo-controlled studies used in regulatory review as well as safety data from clinical trials and postmarketing surveillance ^[1]^[3]^[4]^[2]. The label includes contraindications, preparation and administration details for the single reconstituted 0.5 mL dose, and new warnings derived from postmarketing observational data ^[1]^[4].

Key Findings

The FDA and prescribing information cite pivotal trial results showing that a single dose of AREXVY reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% in the primary analysis and reduced the risk of severe RSV-associated LRTD by 94.1% in the trial dataset reported for the first RSV season; these efficacy estimates formed the basis for regulatory assessment and are reported in the FDA materials summarizing clinical outcomes ^[3].
The pivotal randomized trial population reported in the prescribing information included approximately 12,467 participants who received AREXVY and 12,499 who received placebo in Study 1, the large placebo-controlled Phase 3 cohort summarized in the labeling ^[1]^[4].
The updated label specifies that participants in the main clinical study will remain in follow-up through three RSV seasons to assess duration of protection and safety with repeat vaccination, per the FDA summary and prescribing information ^[3]^[1].

Safety & Tolerability

The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY; the GBS finding is included in the WARNINGS and PRECAUTIONS section of the prescribing information and highlighted in FDA safety communications ^[1]^[4]^[2].
Injection site pain 76.0% in individuals 18 through 49 years of age was among the most commonly reported reactions in that age group in clinical trials ^[1].
Myalgia 59.9% was reported in participants 18 through 49 years of age ^[1].
Fatigue 59.6% was reported in participants 18 through 49 years of age ^[1].
Headache 43.6% was reported in participants 18 through 49 years of age ^[1].
Arthralgia 28.3% was reported in participants 18 through 49 years of age ^[1].
Atrial fibrillation within 30 days of vaccination was reported in 10 participants who received AREXVY and 4 participants who received placebo in the clinical trial dataset presented to the FDA ^[3].

Study Design

The primary evidence base cited in the label includes Study 1, a randomized, placebo-controlled Phase 3 clinical study of adults 60 years of age and older that enrolled 24,966 participants overall (AREXVY N = 12,467; placebo N = 12,499) and additional studies and immunogenicity cohorts that included adults 18 through 59 years with medical conditions that increase risk for LRTD caused by RSV; trial identifiers and study descriptions are included in the prescribing information ^[1]^[4]. The FDA press materials report efficacy estimates from the first RSV season of follow-up and note ongoing follow-up through three RSV seasons to assess duration and repeat‑vaccination safety and effectiveness ^[3]^[1]. Details on randomization ratios, stratification factors, and full statistical analysis plans are provided in the full regulatory review documents and the prescribing information ^[1]^[4]^[3].

FAQ

Q1 What is AREXVY (AREXVY) approved for?

AREXVY is approved as an active immunization to prevent lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older, and in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. The updated prescribing information specifies that AREXVY is not for use in pregnant individuals. Clinicians should consult current prescribing information for complete dosing guidance.

Q2 How does AREXVY work?

[Information] was not available in the provided source excerpts.

Q3 What is the recommended dose of AREXVY?

After reconstitution, a single dose of AREXVY is 0.5 mL for the vial and vial presentation or approximately 0.5 mL for the vial and prefilled syringe presentation, administered intramuscularly as described in the prescribing information. The label provides preparation and administration steps for reconstitution and storage after reconstitution; the prescribing information should be consulted for complete preparation and administration instructions. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects?

In clinical trials, the most commonly reported adverse reactions in participants 18 through 49 years of age included injection site pain 76.0%, myalgia 59.9%, fatigue 59.6%, headache 43.6%, and arthralgia 28.3%. The label also notes a postmarketing observational study suggesting an increased risk of Guillain-Barré syndrome during the 42 days following vaccination, and atrial fibrillation within 30 days was reported in 10 vaccine recipients versus 4 placebo recipients in pivotal trial datasets. Clinicians should consult current prescribing information for complete dosing guidance.

AREXVY Expanded for Adults 18–59 at Increased RSV Risk

Direct Clinical Takeaway & Evidence Summary

AREXVY Expanded for Adults 18–59 at Increased RSV Risk

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Infectious Disease in your inbox.

Related Clinical Updates

FDA Expands AREXVY to Adults 18–59 at Increased RSV Risk

FDA Approves zoliflodacin for Uncomplicated Urogenital Gonorrhea: 90.9% Microbiologic Cure

FDA Approves doravirine/islatravir for Virologically Suppressed HIV‑1: 1% ≥50 copies/mL

Verified HCP Portal